A panel discussion focused on how the 21st Cures Act has increased focus on real-world evidence (RWE), from an educational symposium sponsored by Cardinal Health during the 22nd Annual ISPOR International Meeting. Within oncology, regulatory issues limit clinical trial participation to 3% of cancer patients who differ from the real-world population. However, RWE is criticized for inadequacies in validating drug label expansions. New methods to address these challenges are discussed.
by Cardinal Health via Endless Supplies .Biz - Brands
No comments:
Post a Comment